The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare, the federal health insurance programme for the elderly.
In a statement on Tuesday, Medicare’s regulator said the government would pay $274 for a 30-day supply of Ozempic and Wegovy, down from $959. The price reduction will go into effect in 2027.
The cost cuts were expected following President Donald Trump’s landmark drug-pricing deal with Novo and rival Eli Lilly announced at the White House earlier this month.
您已閱讀25%（561字），剩余75%（1684字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。